Truqap Use In Pregnancy & Lactation

Women of childbearing potential/Contraception in males and females: Women of childbearing potential should be advised to avoid becoming pregnant while receiving TRUQAP. A pregnancy test should be performed on women of childbearing potential prior to initiating treatment and verified as negative. Re-testing should be considered throughout treatment.
Patients should be advised to use effective contraception during the use of TRUQAP and for the following periods after completion of treatment with TRUQAP: at least 4 weeks for females and 16 weeks for males.
Pregnancy: There are no data from the use of TRUQAP in pregnant women. Studies in animals have shown reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). Therefore, TRUQAP is not recommended during pregnancy and in women of childbearing potential not using contraception.
Breast-feeding: It is not known whether capivasertib or its metabolites are excreted in human milk. Exposure to capivasertib was confirmed in suckling rat pups which may indicate the excretion of capivasertib in milk. A risk to the breast-fed child cannot be excluded (see Pharmacology: Toxicology: Preclinical safety data under Actions). Breast-feeding should be discontinued during treatment with TRUQAP.
Fertility: There are no clinical data on fertility. In animal studies, no adverse effect on female reproductive organs was observed, but the effect on female fertility in rats was not studied. Capivasertib has resulted in testicular toxicity and may impair fertility in males of reproductive potential (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Refer to section 4.6 of the prescribing information for fulvestrant.